4,042 reports of this reaction
2.1% of all MACITENTAN reports
#9 most reported adverse reaction
HOSPITALISATION is the #9 most commonly reported adverse reaction for MACITENTAN, manufactured by Actelion Pharmaceuticals US, Inc.. There are 4,042 FDA adverse event reports linking MACITENTAN to HOSPITALISATION. This represents approximately 2.1% of all 188,657 adverse event reports for this drug.
Patients taking MACITENTAN who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for MACITENTAN, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for MACITENTAN:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 4,042 FDA reports for MACITENTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 2.1% of all adverse event reports for MACITENTAN, making it a notable side effect.
If you experience hospitalisation while taking MACITENTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.